WEBULL
News
ARQT
26.17
-1.58%
-0.42
Have Insiders Sold Arcutis Biotherapeutics Shares Recently?
Simply Wall St · 1d ago
Why Arcutis Biotherapeutics (ARQT) Is Up 5.1% After Positive Infant Atopic Dermatitis Trial Results And What's Next
Simply Wall St · 2d ago
Weekly Report: what happened at ARQT last week (0202-0206)?
Weekly Report · 3d ago
Arcutis ZORYVE Infant Data Adds New Dimension To Atopic Dermatitis Thesis
Simply Wall St · 6d ago
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit
The Motley Fool · 6d ago
Arcutis Biotherapeutics Grants 94,000 Restricted Stock Units to New Employees
Reuters · 6d ago
ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 6d ago
Director Howard G. Welgus Reports Sale of Arcutis Biotherapeutics Common Shares
Reuters · 02/05 00:23
Will Positive Infant Phase 2 ZORYVE Data Expand Arcutis Biotherapeutics' (ARQT) Atopic Dermatitis Narrative?
Simply Wall St · 02/03 00:36
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
TipRanks · 02/02 17:36
Arcutis Reports Positive Phase 2 Data For ZORYVE Cream 0.05% In Infants With Atopic Dermatitis
NASDAQ · 02/02 13:29
Arcutis Biotherapeutics Announces ZORYVE Was Well Tolerated With Consistent Safety Profile In Clinical Trial Of INTEGUMENT-INFANT Phase 2 Study
Benzinga · 02/02 13:12
Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve
TipRanks · 02/02 13:06
Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream in Infants with Atopic Dermatitis
Reuters · 02/02 13:00
ARCUTIS BIOTHERAPEUTICS INC - PLANS TO SUBMIT SNDA FOR ZORYVE CREAM IN Q2 2026
Reuters · 02/02 13:00
ARCUTIS ANNOUNCES POSITIVE TOPLINE RESULTS FOR INTEGUMENT-INFANT PHASE 2 TRIAL OF ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH MILD TO MODERATE ATOPIC DERMATITIS
Reuters · 02/02 13:00
ARCUTIS BIOTHERAPEUTICS INC: INVESTIGATIONAL ZORYVE CREAM 0.05% WAS WELL TOLERATED
Reuters · 02/02 13:00
Weekly Report: what happened at ARQT last week (0126-0130)?
Weekly Report · 02/02 10:13
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 01/29 12:40
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.